Adial Pharmaceuticals (ADIL) vs CytoMed Therapeutics (GDTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CytoMed Therapeutics (GDTC) has outperformed Adial Pharmaceuticals (ADIL) over the past year, losing 56.5% versus a loss of 60.3%. CytoMed Therapeutics is the larger company by market cap ($11.3 million vs $10.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADIL | GDTC |
|---|---|---|
| Share price | $3.97 | $0.9449 |
| Market cap | $10.42M | $11.28M |
| 1-day change | -0.50% | -3.56% |
| YTD return | -27.82% | -29.22% |
| 1-year return | -60.30% | -56.46% |
| 5-year return | -99.84% | — |
| EPS (TTM) | $-20.65 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.50 | $3.68 |
| 52-week low | $1.31 | $0.68 |
| Distance from 52-week high | -62.19% | -74.32% |
| Analyst consensus | none | none |
| Avg. price target upside | +109.82% | +340.26% |
| Average volume | 56.16K | 78.66K |
| Shares outstanding | 2.63M | 11.93M |
| Employees | 5 | 42 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Adial Pharmaceuticals
ADIL stock →Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
ADIL vs GDTC FAQ
Which is bigger, Adial Pharmaceuticals or CytoMed Therapeutics?
CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $11.28M compared with $10.42M for Adial Pharmaceuticals (ADIL).
Which stock has performed better over the past year, ADIL or GDTC?
GDTC returned -56.46% over the past 12 months, compared with -60.30% for ADIL (price return, excluding dividends). Past performance does not predict future results.
Are Adial Pharmaceuticals and CytoMed Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.